NASDAQ:XBIO

Xenetic Biosciences Q4 2024 Earnings Results & Report

Xenetic Biosciences logo
$1.40 -0.14 (-9.09%)
Closing price 11/20/2026 03:47 PM Eastern
Extended Trading
$1.46 +0.06 (+3.93%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenetic Biosciences missed analyst earnings expectations but beat on revenue in its Q4 2024 results, released March 18, 2025. The company reported EPS of -$0.68 versus the -$0.20 consensus estimate, while revenue of $650 thousand topped the $182 thousand estimate by $468 thousand.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
8:00 AM ET

Xenetic Biosciences EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.20
Beat/Miss
Missed by -$0.48
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Xenetic Biosciences Revenue Results

Actual Revenue
$650 thousand
Expected Revenue
$182 thousand
Beat/Miss
Beat by +$468.00 thousand
YoY Revenue Growth
N/A

Xenetic Biosciences Q4 2024 Earnings FAQ

Xenetic Biosciences (NASDAQ:XBIO) reported earnings of -$0.68 per share for Q4 2024, missing the consensus estimate of -$0.20. The report was announced on Tuesday, March 18, 2025.

Xenetic Biosciences reported revenue of $650 thousand for Q4 2024, against a consensus estimate of $182 thousand.

Xenetic Biosciences Earnings Headlines

Contrasting Xenetic Biosciences (XBIO) and Its Peers
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO) is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells.

The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

View Xenetic Biosciences Profile